Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.

Background: HER2 overexpression is an unfavorable prognostic factor in patients with breast cancer, but it is also a target for the monoclonal antibody trastuzumab, which is effective in adjuvant and palliative settings. HER2 positivity is an inclusion criterion for immunotherapy, but it is not a positive predictive factor, and only half of patients benefit from the treatment.

Aim: The aim of this study was to evaluate the prognostic and predictive value of HER3, PTEN and phosphorylated HER2 (p-HER2) expression in primary breast tumors of patients treated with trastuzumab in an adjuvant or palliative regimen.

HER2 molecular subtype is a dominant subtype of mammary Paget's cells. An immunohistochemical study.

Aims:   To test the hypothesis that the similarity of the molecular subtypes of Paget's cells to the molecular subtypes of the underlying breast carcinomas favours the epidermotrophic theory of the origin of Paget's cells.

Methods And Results:   The immunohistochemical expression of markers that define particular molecular subtypes of breast carcinomas were analysed. The whole analysis was performed by means of tissue microarrays in mammary Paget's disease and in the underlying breast carcinoma(s).

Does vimentin help to delineate the so-called 'basal type breast cancer'?

Background: Vimentin is one of the cytoplasmic intermediate filament proteins which are the major component of the cytoskeleton. In our study we checked the usefulness of vimentin expression in identifying cases of breast cancer with poorer prognosis, by adding vimentin to the immunopanel consisting of basal type cytokeratins, estrogen, progesterone, and HER2 receptors.

Methods: 179 tissue specimens of invasive operable ductal breast cancer were assessed by the use of immunohistochemistry.

Prognostic relevance of cyclin E expression in operable breast cancer.

Background: Cyclin E is an important regulator of cell-cycle progression. High levels of cyclin E protein in breast cancer have been reported in association with higher disease stage, poor histological differentiation of tumor, and lack of steroid receptors. Data concerning the prognostic relevance of cyclin E expression in breast cancer are conflicting.

Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.

We describe a unique case of a 67-year-old patient with primary uterine rhabdomyosarcoma with a history of breast cancer and gastrointestinal stromal tumor of the stomach. Uterine rhabdomyosarcoma was diagnosed in our patient during adjuvant treatment of breast cancer with anastrozole. To the best of our knowledge, the development of primary uterine rhabdomyosarcoma has never been described in patients treated with anastrozole.

Recurrence of cholangiogenous carcinoma in port-sites two years after laparoscopic removal of noncancerous gallbladder.

We present a unique case of carcinoma diagnosed in port-site, two years after uncomplicated laparoscopic cholecystectomy for benign cholecystitis. Analysis of morphology and cytokeratin profile (CK19+ and CK20+/-) of resected port-site tumor allows us to establish the diagnosis of tubular carcinoma with probable cholangiogenic origin. The primary carcinoma was not diagnosed in archival gallbladder tissue, despite repeated histological examination.

Relationship of P-cadherin expression to basal phenotype of breast carcinoma.

Background: P-cadherin (P-CD) is a molecule expressed mainly by basal cells involved in cell adhesion. We evaluated expression of P-CD in operable breast carcinomas and its relationship with immunohistochemical markers of the basal-like phenotype and with clinical outcome.

Material And Methods: Expression of P-CD was analyzed by immunohistochemistry in 194 tissue specimens of invasive operable ductal breast cancer.

[Breast neoplasm in men and women--prognosis comparison].

Unlabelled: Male breast cancer is a rare disease, therefore our knowledge of the disease is limited.

Aim: Comparison of prognosis of male breast cancer and not-otherwise specified (NOS) invasive ductal female breast cancer and invasive lobular female breast cancer.

Material And Methods: From 1.